Evidence map›Paper›PMID 25298578›Full record

Trial reportIndian journal of pharmacology

Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia.

Somnath Maity, Supriyo Choudhury, Avijit Hazra, Amal Kanti Das

Abstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. ACG and CAG Clinical Guideline: Management of Dyspepsia.The American journal of gastroenterology · 2017
    Guideline
  2. The use of antihistamine and antihistamine-like drugs for cancer-related pain: a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Somnath MaityDepartment of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India.
Supriyo ChoudhuryDepartment of Pharmacology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India.
Avijit HazraDepartment of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India.
Amal Kanti DasDepartment of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India.
Institute of Post Graduate Medical Education and Research · INCollege of Medicine & Sagore Dutta Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesLafutidine is a new H2-blocker in India claimed to be more potent and effective than existing H2-blockers. Proton pump inhibitors (PPIs), by virtue of their mechanism of action, have greater efficacy than H2-blockers in gastric acid suppression. However, clinical trials comparing H2-blockers directly with PPIs are limited. We carried out a head-to-head comparison of the effectiveness of lafutidine versus the PPI pantoprazole in uninvestigated dyspepsia [CTRI/2013/12/004261]. MATERIALS AND

methodsA prospective, open label, randomized, controlled trial was conducted in a tertiary care hospital. Ambulatory adult patients with dyspepsia, not yet subjected to endoscopy, were recruited if they had at least moderately severe symptoms, defined as a score of ≥ 4 on a 7-point Global Overall Symptom (GOS) Scale. Those with alarm features or significant comorbidity were excluded. Subjects received either once daily lafutidine 10 mg or pantoprazole 40 mg, orally, for 8 weeks. Reflux, dysmotility and pain scores were assessed by Modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (mFSSGERD), and quality of life (QoL) by SF-8 scale. The latter had physical and mental components summarized by physical component summary score (PCS) and a mental component summary score (MCS).

resultsOf 122 patients enrolled, data of 57 on lafutidine and 60 on pantoprazole were analyzed. At 4 weeks, proportion of subjects responding (GOS score ≤ 2) in the two arms (lafutidine 45.61% vs. pantoprazole 48.33%, P = 0.854) or showing symptom resolution (GOS score ≤ 1) (lafutidine 12.28% vs. pantoprazole 5.00%; P = 0.197) were comparable. Similarly at 8 weeks, both responder (lafutidine 52.63% vs. pantoprazole 56.67%; P = 0.712) and symptom resolution proportions (lafutidine 33.33% vs. pantoprazole 30%; P = 0.843) were comparable. Total score on mFSSGERD scale, as well as all its three component scores, and PCS and MCS scores on QoL SF-8 scale showed improvement but no statistically significant difference between the two arms. Tolerability of both drugs was excellent.

conclusionsLafutidine is well-tolerated and there is no clinically worthwhile difference between the two drugs in the empirical treatment of uninvestigated dyspepsia.

Indexed as

2-PyridinylmethylsulfinylbenzimidazolesAcetamidesAdultDyspepsiaFemaleFollow-Up StudiesGastroesophageal RefluxHistamine H2 AntagonistsHumansIndiaMaleMiddle AgedPantoprazolePiperidinesProspective StudiesProton Pump Inhibitors2-PyridinylmethylsulfinylbenzimidazolesAcetamidesHistamine H2 AntagonistslafutidinePantoprazolePiperidinesProton Pump InhibitorsPyridinesDyspepsialafutidinepantoprazolerandomized controlled trial

Identifiers

PMID25298578
PMCPMC4175885
OpenAlexW2162143051

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.